Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer

by Knudsen, Erik S., Witkiewicz, Agnieszka K.
Published 2014

Biological specificity of CDK4/6 inhibitors: dose response relationship, <i>in vivo</i> signaling, and composite response signature

by Knudsen, Erik S., Hutcheson, Jack, Vail, Paris, Witkiewicz, Agnieszka K.
Published 2017

Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential

by Knudsen, Erik S., Balaji, Uthra, Freinkman, Elizaveta, McCue, Peter, Witkiewicz, Agnieszka K.
Published 2015

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

by Witkiewicz, Agnieszka K., Chung, Sejin, Brough, Rachel, Vail, Paris, Franco, Jorge, Lord, Christopher J., Knudsen, Erik S.
Published 2018

Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?

by Valsecchi Matias E, Holdbrook Thomas, Leiby Benjamin E, Pequignot Edward, Littman Susan J, Yeo Charles J, Brody Jonathan R, Witkiewicz Agnieszka K
Published 2012-03-01

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.

by Witkiewicz, Agnieszka K, Balaji, Uthra, Eslinger, Cody, McMillan, Elizabeth, Conway, William, Posner, Bruce, Mills, Gordon B, O'Reilly, Eileen M, Knudsen, Erik S
Published 2016

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer

by Witkiewicz, Agnieszka K., Balaji, Uthra, Eslinger, Cody, McMillan, Elizabeth, Conway, William, Posner, Bruce, Mills, Gordon B., O’Reilly, Eileen M., Knudsen, Erik S.
Published 2016